Cat. No. | Product name | CAS No. |
DC10018 |
Atrasentan hydrochloride
Featured
Atrasentan Hcl(A-147627) is an endothelin antagonist receptor (IC50=0.0551 nM, ETA) being developed for the treatment of prostate cancer. |
195733-43-8 |
DC22004 |
ATV399
ATV399 (ATV-399) is a novel small molecule that dose-dependently reduces the cleaved caspase9 levels with IC50 of 3.3 uM, inhibits dimerization of iNOS. |
393834-37-2 |
DC20114 |
ATWLPPR Peptide TFA
ATWLPPR Peptide TFA, a heptapeptide, acts as a selective neuropilin-1 inhibitor, inhibits VEGF165 binding to NRP-1, used in the research of angiogenesis. ATWLPPR Peptide TFA has potential in reducing the early retinal damage caused by diabetes. |
|
DC23401 |
AU1
AU1 (GSK 1379725A) is the first selective small molecule inhibitor of BPTF bromodomain (bromodomain PHD finger transcription factor) with Kd of 2.8 uM in a cell-based reporter assay, shows no binding activity for Brd4. |
1802251-00-8 |
DC10552 |
AU1235
Featured
AU1235 is an adamantyl urea inhibitor of Mycobacterium tuberculosis. |
1338780-86-1 |
DC21865 |
Aumitin
Featured
Aumitin is a novel potent autophagy inhibitor with IC50 of 124 and 244 nM against starvation- and rapamycin- induced autophagy respectively, targets mitochondrial complex I. |
946293-78-3 |
DC12428 |
AUNP-12
Featured
AUNP-12 (Aurigene-012) is a PD-1 inhibitor peptide, blocks the PD-1/PD-L1, PD-1/PD-L2 and PD-L1/CD80 pathways. |
1353563-85-5 |
DC26036 |
Aurantiamide acetate
Aurantiamide acetate suppresses the growth of malignant gliomas in vitro and in vivo by inhibiting autophagic flux. |
56121-42-7 |
DC20312 |
Aurintricarboxylic acid
Aurintricarboxylic acid (ATA) is a potent small molecule inhibitor of RISC loading with IC50 of 0.47 uM, inhibits RISC activity against transiently expressed reporters and endogenous genes. |
4431-00-9 |
DC10138 |
Auristatin E
Featured
Auristatin E is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAE analog and cytotoxin in Antibody-drug conjugates. |
160800-57-7 |
DC7964 |
Aurora A Inhibitor I
Featured
Aurora A inhibitor I is a selective Aurora A inhibitor (Aurora A: IC50=0.0034 μM; Aurora B IC50=3.4 μM), (B/A ratio=1000). |
1158838-45-9 |
DC20037 |
Aurora inhibitor 1
Aurora inhibitor 1 is a potent Aurora inhibitor with an IC50 of ≤ 4 nM and ≤13 nM for Aurora A and Aurora B kinase, respectively. |
2227019-45-4 |
DC26118 |
AKI-7169(Aurora Kinase Inhibitor III)
Featured
Aurora kinase inhibitor III is a potent inhibitor of Aurora A kinase (IC50 = 42 nM). |
879127-16-9 |
DC11999 |
AUT-1
Featured
AUT-1 is a novel specific, cell permeant modulator of Kv3 channels with EC50 of 4.7 and 4.9 uM for Kv3.1b and Kv3.2a, respectively. |
1311136-84-1 |
DC10548 |
Auten-99
Featured
Auten-99 is a novel inhibitor of the myotubularin phosphatase Jumpy (also called MTMR14), acrossing the blood-brain barrier and exerting potent neuroprotective effects. |
1049780-58-6 |
DC10461 |
Autophinib
Featured
Autophinib is a novel potent autophagy inhibitor, inhibiting autophagy induced by starvation or Rapamycin by targeting the lipid kinase VPS34. |
1644443-47-9 |
DC21866 |
Autotaxin inhibitor 12
Autotaxin inhibitor 12 is a highly potent, selective, orally-bioavailable inhibitor of autotaxin with IC50 of 3.1 nM in choline release assays. |
1613513-14-6 |
DC20701 |
Autotaxin inhibitor compound 1
Autotaxin inhibitor compound 1 (Autotaxin-IN-1) is a potent, selective, orally bioavailable inhibitor of autotaxin with IC50 of 2.2 nM in ex vivo human whole blood assay, does not inhibit related proteins ENPP1 and ENPP7. |
1619971-30-0 |
DC22219 |
Auxin agonist RN3
Auxin agonist RN3 (RubNeddin 3) is a potent, selective auxin agonist that induces specific AUX/IAA protein degradation to modulate plant development. |
425609-03-6 |
DC22220 |
Auxin agonist RN4
Auxin agonist RN4 (RubNeddin 4) is a potent, selective auxin agonist that induces specific AUX/IAA protein degradation to modulate plant development. |
433950-87-9 |
DC5202 |
Luminespib (NVP-AUY922)
Featured
AUY922 (NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Phase 1/2. |
747412-49-3 |
DC8253 |
AV-412(MP-412)
AV-412(MP-412) is a potent dual inhibitor of EGFR and ErbB2(IC50=19 nM) tyrosine kinases, including the mutant EGFR(L858R IC50=0.51 nM, T790M IC50=0.79 nM); inhibits autophosphorylation of EGFR and ErbB2 with IC(50) of 43 and 282 nM, respectively. |
451492-95-8 |
DC8799 |
Avanafil(TA-1790)
Featured
Avanafil(TA-1790) is a potent and highly selective phosphodiesterase-5(PDE-5) inhibitor(IC50=5.2 nM) for erectile dysfunction; lower selectivity against PDE1, PDE6, and PDE11. |
330784-47-9 |
DC22012 |
Avanbulin
Avanbulin (BAL27862, BAL-27862) is a novel microtubule-destabilizing agent that potently inhibits tubulin assembly at 37°C with IC50 of 1.4 uM in tubulin-binding assays. |
798577-91-0 |
DC1094 |
Avasimibe
Featured
Avasimibe inhibits ACAT and CYP2C9 with IC50 of 3.3 μM and 2.9 μM, respectively. |
166518-60-1 |
DC20703 |
AVE-0118
AVE-0118 is a potent I(to)/I(Kur) blocker, Kv1.5 channel inhibitor with IC50 of 5.6 uM, also blocks Kv1.3, Kv2.1, Kv3.1, and Kv4.3 channels with similar potency. |
498577-53-0 |
DC10732 |
Anavex-2-73 free base (Blarcamesine)
Featured
AVex-73 is a muscarinic M1 agonist potentially for the treatment of Alzheimer's disease |
195615-83-9 |
DC12715 |
AVG-233
AVG-233 (AVG233) is a potent, allosteric inhibitor of respiratory syncytial virus (RSV) RNA-dependent RNA polymerase (RdRp) complex, demonstrates nanomolar activity against both laboratory-adapted RSV strains and clinical RSV isolates (EC50=34-79 nM). |
2151937-80-1 |
DC8351 |
Avibactam sodium
Featured
Avibactam sodium(NXL-104) is a non-β-lactam β-lactamase inhibitor antibiotic. |
1192491-61-4 |
DC10009 |
Avitinib free base
Featured
Avitinib is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. |
1557267-42-1 |
DC10008 |
Avitinib maleate
Featured
Avitinib is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. |
1557268-88-8 |
DC24068 |
AVL-292 besylate
Featured
AVL-292 besylate (Spebrutinib, CC-292) is a highly selective, covalent Btk inhibitor with IC50 of <1 nM. |
1360053-81-1 |
DC5014 |
AVL-292
Featured
AVL-292 is a covalent, highly selective, orally active small molecule inhibitor of Btk currently being evaluated in a Phase 1b clinical trial in relapsed. |
1202757-89-8 |
DC11399 |
AVN-492
Featured
AVN-492 is a very specific and highly-selective antagonist with picomolar affinity to 5-HT6R (Ki=91 pM). |
1220646-23-0 |
DC8565 |
AVN944
Featured
AVN-944(VX-944) is a selective, noncompetitive inhibitor of the enzyme directed against human IMPDH with Ki of 6-10 nM for IMPDH1/IMPDH2. |
297730-17-7 |
DCAPI1313 |
Avobenzone(Parsol 1789)
Avobenzone(Parsol 1789) |
70356-09-1 |
DC9436 |
Avosentan
Avosentan(Ro 67-0565; SPP-301) is a potent, selective endothelin receptor(ETA receptor) antagonist. |
290815-26-8 |
DC26015 |
Deudextromethorphan
Featured
AVP-786 is a novel, next-generation investigational drug product consisting of a combination of deudextromethorphan, and an ultra-low dose of quinidine. |
1079043-55-2 |
DC20709 |
AW-814141
AW-814141 is a potent, selective and orally active inhibitor of p38 MAP kinase with IC50 of 100 nM/158 nM for p38α/p38β. |
905285-51-0 |
DC7071 |
AWD 131-138(Imepitoin)
Featured
AWD 131-138(Imepitoin) is a new low-affinity partial benzodiazepine receptor agonist with potent anticonvulsant and anxiolytic properties in rodent models. |
188116-07-6 |
DC20243 |
AWZ1066S
Featured
AWZ1066S is a highly specific anti-Wolbachia drug candidate for a short-course treatment of filariasis. |
2239272-16-1 |
DC11802 |
AX-024 free base
Featured
AX-024 is an cytokine release inhibitor which can strongly inhibit the production of interleukin-6 (IL-6), tumor necrosis factor-α (TNFα), interferon-γ (IFN-γ), IL-10 and IL-17A. |
1370544-73-2 |
DC10545 |
AX-024 HCl
Featured
AX-024 is the first-in-class inhibitor of T cell receptor (TCR); AX-024 is an orally available inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation (IC50 value 1 nM). |
1704801-24-0 |
DC10649 |
AX15836
Featured
AX15836 is a highly potent and selective ERK5 inhibitor. |
2035509-96-5 |
DC10412 |
AX20017
Featured
AX20017 is a small-molecule protein kinase G (PknG) inhibitor with an IC50 of 0.39 μM. |
329221-38-7 |
DCAPI1524 |
Axitinib
Featured
Axitinib is a non-selective receptor kinase inhibitor of Flt and Flk proteins. This compound also inhibits VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-β and c-KIT with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM, respectively. Axitinib is studied as an ant |
319460-85-0 |
DC20313 |
Axl-IN-21
Axl-IN-21 is a selective and potent inhibitor of wild-type Axl with IC50 of 2.2 nM. |
2086274-31-7 |
DC23895 |
AY-9944
Featured
AY 9944 is a specific cholesterol biosynthesis inhibitor. AY 9944 inhibits the 7-dehydro cholesterol Δ7-reductase (DHCR7) enzyme (IC50=13 nM). AY 9944 causes hypocholesterolemia and accumulation of 7DHC. At high doses, AY 9944 inhibits also in cultured embryos sterol Δ7-Δ8 isomerase, which causes the accumulation of cholest-8-en-3β-ol. |
366-93-8 |
DC11371 |
AY-NH2
Featured
AY-NH2 is a peptide agonist of proteinase-activated receptor 4 (PAR4) that induces aggregation of rat and human platelets in vitro (EC50s = 15 and 60 μM, respectively). |
352017-71-1 |
DC23879 |
AZ 4800
AZ 4800 is a potent γ-secretase modulator that reduces Aβ40 and Aβ42 levels in HEK/APPswe cells with IC50 of 26 nM and 60 nM, also decreases Aβ39, whereas increases both Aβ37 and Aβ38.. |
1226886-78-7 |
DC7367 |
AZ-960
Featured
AZ 960 is a novel ATP competitive JAK2 inhibitor with IC50 and Ki of <3 nM and 0.45 nM, 3-fold selectivity of AZ960 for JAK2 over JAK3. |
905586-69-8 |
DC20710 |
AZ0108
AZ0108 is an orally bioavailable phthalazinone PARP inhibitor with enzyme IC50 of <30/<30/83 nM for PARP1/2/6 respectively. |
1825345-52-5 |
DC11147 |
AZ084
AZ084 (AZ-084) is a potent, selective, allosteric, orally available CCR8 antagonist with Ki of 0.9 nM. |
929300-19-6 |
DC20314 |
AZ-1
AZ-1 is a small molecule inducer of ABCA1 and apoE that act through indirect activation of the LXR pathway, shows purinergic receptor P2X7 antagonist activity. |
803735-54-8 |
DC11975 |
AZ 10397767
AZ10397767 is a potent, selective CXCR2 inhibitor that inhibits CXCL8 binding to CXCR2 with pIC50 of 9.0. |
333742-63-5 |
DC20711 |
AZ10606120 dihydrochloride
Featured
AZ10606120 is a potent, specific P2X7 receptor antagonist with Kd of 1.4 and 19 nM at human and rat P2X7 receptors respectively. |
607378-18-7 |
DC12613 |
AZ12204657
AZ12204657 (AZ-12204657) small-molecule GPR44 antagonist, displaces the binding of [3H]PGD2 from membranes of HEK293 cells transfected with human recombinant GPR44 with IC50 of 2.5 nM. |
847148-49-6 |
DC22724 |
AZ12441970
AZ12441970 is a selective TLR7 agonist with pEC50 of 6.8 and 6.6 for human and rat TLR7, shows inactivity against TLR8. |
929551-91-7 |
DC12530 |
AZ12601011
AZ12601011 (AZ-12601011) is a potent, selective inhibitor of ALK4, ALK7 and TGFBR1 (Kd=2.9 nM), inhibits TGFβ-induced reporter activity with IC50 of 18 nM. |
|
DC12531 |
AZ12799734
AZ12799734 (AZ-12799734) is a pan BMP/TGFβ inhibitor that potently inhibits ligand activated SMAD3/4 transcription with IC50 of 47 nM, inhibits receptor-mediated phosphorylation of SMAD1 by ALK1, BMPR1A and BMPR1B and phosphorylation of SMAD2 by ALK4, TGF |
1117684-36-2 |
DC21406 |
AZ-1355
AZ-1355 is an effctive lipid-lowering compound that inhibits platelet aggregation in vivo and elevates the prostaglandin I2/thromboxane A2 ratio in vitro.. |
75451-07-9 |
DC20712 |
AZ13705339
Featured
AZ13705339 is a potent, selective PAK1 inhibitor with IC50 of 0.33 nM, displays 14-, 470-, 4100- and 2600-fold selectivity over Src, FGFR1, KDR and PAK4. |
2016806-57-6 |
DC20713 |
AZ13711265
AZ13711265 is a potent, selective, in vivo active PAK1 inhibitor with IC50 of 0.58 nM, displays 880-, 2100- and 90-fold selectivity over Src, FGFR1, KDR and PAK4. |
2016806-55-4 |
DC23484 |
AZ1729
AZ1729 is a novel direct, positive allosteric modulator of fatty acid receptor FFA2 (pEC50=6.9), selectively activates Gi signaling but lacks the capacity to activate FFA2 Gq/G11-mediated signaling pathways. |
2016864-46-1 |
DC7746 |
AZ191
Featured
AZ191 is a potent and selective DYRK1B inhibitor with IC50 of 17 nM, about 5- and 110-fold selectivity over DYRK1A and DYRK2, respectively. |
1594092-37-1 |
DC20315 |
AZ-2
AZ-2 is a small molecule inducer of ABCA1 and apoE that act through indirect activation of the LXR pathway, shows purinergic receptor P2X7 antagonist activity. |
788146-30-5 |
DC7906 |
AZ20
Featured
AZ20 is a novel potent and selective inhibitor of ATR kinase with IC50 of 5 nM, 8-fold selectivity over mTOR. |
1233339-22-4 |
DC23855 |
AZ-23
AZ-23 is a potent, selective, orally bioavailable Trk kinase inhibitor with IC50 of 2 and 8 nM for TrkA and TrkB, respectively. |
915720-21-7 |
DC12376 |
AZ304
Featured
AZ304 is a novel potent, dual BRAF inhibitor targeting the kinase domains of wild type BRAF, V600E mutant BRAF and wild type CRAF with IC50 of 79 nM, 38 nM and 68 nM, respectively. |
942507-42-8 |
DC10906 |
AZ31
Featured
AZ31 is a novel ATM inhibitor. |
2088113-98-6 |
DC7072 |
AZ3146
Featured
AZ3146 is a potent and selective monopolar spindle 1 (Mps1) kinase inhibitor (IC50 = 35 nM); less potent to FAK, JNK1, JNK2, and Kit. |
1124329-14-1 |
DC10891 |
AZ-32
Featured
AZ32 is an orally bioavailable and blood-brain-barrier penetrating ATM inhibitor (AZ32) that radiosensitizes intracranial gliomas in mice. |
2288709-96-4 |
DC9667 |
AZ-33(AZ33)
Featured
AZ-33 is a inhibitor of LDH-A with an IC50 of 0.5 μM. |
1370290-34-8 |
DC10879 |
AZ3451
Featured
AZ3451 is a potent and selective allosteric antagonist of protease-activated receptor 2 (PAR2) |
2100284-59-9 |
DC20715 |
AZ-4217
AZ-4217 is a potent and selective, orally active, brain-permeable BACE1 inhibitor with IC50 of 160 pM in human SH-SY5Y cells. |
1383846-83-0 |
DC22293 |
AZ-505 ditrifluoroacetate
Featured
AZ505 ditrifluoroacetate is a potent and selective SMYD2 inhibitor with IC50 of 0.12 μM. |
1035227-44-1 |
DC8537 |
AZ505
Featured
AZ505 is a potent and highly selective inhibitor of the oncogenic protein SMYD2(IC50=0.12 uM) with potential anticancer activity, >600 fold than SMYD3(IC50>83.3 uM); DOT1L(IC50>83.3 uM);EZH2(IC50>83.3 uM). |
1035227-43-0 |
DC8052 |
AZ5104
Featured
AZ5104 is an active circulating metabolite of AZD9291. |
1421373-98-9 |
DC7926 |
AZ-6102
Featured
AZ6102 is a potent TNKS1/2 inhibitor that has 100-fold selectivity against other PARP family enzymes and shows 5 nM Wnt pathway inhibition in DLD-1 cells. |
1645286-75-4 |
DC10985 |
AZ6197
AZ6197 (AZ-6197) is a potent, selective, reversible inhibitor of ERK1/2 with IC50 of <0.3 nM (ERK2), inhibits pERK/pRSK with IC50 of 12/62 nM in A375 cells, respectively. |
2023003-94-1 |
DC8842 |
AZ-7371(DprE1-IN-1)
Featured
AZ-7371(DprE1-IN-1) is a novel non-covalent DprE1 inhibitor. |
1494675-86-3 |
DC12274 |
AZ82
AZ82 is a selective HSET/KIFC1 inhibitor, with a Ki of 43 nM and an IC50 of 300 nM for KIFC1. |
1449578-65-7 |
DC12677 |
AZ876
Featured
AZ876 is a novel high-affinity LXR agonist. |
898800-26-5 |
DC11742 |
AZ-8838
AZ-8838 (AZ8838) is a potent, and selective PAR2 antagonist with Kd of 125 nM. |
2100285-41-2 |
DC23407 |
AZ8838 racemate
AZ8838 racemate(AZ-8838 racemate) is the racemate form of AZ8838, which is a potent, and selective PAR2 antagonist with Kd of 125 nM.. |
2100283-63-2 |
DC10056 |
AZ9482
Featured
AZ9482, a potent and selective PARP inhibitor featuring an amide linkage to a 2-piperazinyl-3-cyano-pyridine. |
1825345-33-2 |
DC8713 |
Azaperone
Azaperone acts as a dopamine antagonist but also has some antihistaminic and anticholinergic properties. Azaperone is a pyridinylpiperazine and butyrophenone neuroleptic drug with sedative and antiemetic effects, which is used mainly as a tranquilizer in |
1649-18-9 |
DCAPI1427 |
Azasetron HCL
Azasetron Hydrochloride is a 5-HT3 receptor antagonist which is used as an anti-emetic. |
123040-16-4 |
DC9469 |
Azatadine (dimaleate)
Azatadine dimaleate is an histamine and cholinergic inhibitor with IC50 of 6.5 nM and 10 nM, respectively. |
3978-86-7 |
DCAPI1182 |
Azathioprine (Azasan, Imuran)
Featured
Azathioprine (Azasan, Imuran) is the analytical standard of Azathioprine. This product is intended for research and analytical applications. Azathioprine (BW 57-322) is an orally active immunosuppressive agent. Azathioprine can be converted in vivo to the active metabolite 6-mercaptopurine (6-MP). Azathioprine has myelosuppressive effects and induces apoptosis. |
446-86-6 |
DC23851 |
AZD 0424
AZD 0424 is an orally bioavailable small molecule tyrosine kinase inhibitor of Abl and Src kinase with potential antineoplastic activity.. |
692054-06-1 |
DC20720 |
AZD 1678
AZD 1678 is a potent, selective orally bioavailable CCR4 receptor antagonist with pIC50 of 8.6 for hCCR4, pIC50 of 9.0 for rCCR4. |
942137-41-9 |
DC23588 |
AZD 3043
AZD 3043 (THRX-918661) is a positive allosteric modulator of the GABAA receptor in vitro and a sedative/hypnotic agent in vivo, potentiates GABAA receptor-mediated chloride currents with EC50 of 36 uM. |
579494-66-9 |
DC8658 |
AZD3264
AZD 3264 is an IkB-kinase IKK2 Inhibitor, IKK2 has been identified as one of the novel pathways to treat inflammatory conditions such as asthma, chronic pulmonary obstructive disorder (COPD) and rheumatoid arthritis. |
1609281-86-8 |
DC20726 |
AZD 4205
Featured
AZD 4205 (AZD4205) is a potent, selective JAK1 inhibitor IC50 of 73 nM and Ki of 2.8 nM, shows high selectivity against JAK2 and JAK3 with IC50 of 13,233 nM and >30,000 nM respectively; shows potent inhibition of p-STAT3 in a cell based assay of JAK1 activity with an IC50 of 128 nM and excellent selectivity across the kinome; reduces residual disease and prolongs the benefit of Osimertinib in lung cancer patients with EGFR activating mutations both in vitro and in vivo. |
2091134-68-6 |
DC20729 |
AZD 5991
Featured
AZD 5991 (AZD5991) is a potent and selective macrocyclic inhibitor of Mcl-1 with sub-nanomolar affinity. |
2143061-81-6 |
DC23722 |
AZD 6610
AZD 6610 is a dual peroxisome proliferator-activated receptor (PPAR) α/γ agonist for treatment of diabetes mellitus.. |
810677-36-2 |
DC20730 |
AZD 7009
AZD 7009 is a novel antiarrhythmic agent that inhibits the late sodium current in CHO K1 cells expressing hNav1.5 with IC50 of 11 uM. |
864368-79-6 |
DC9309 |
AZD-0156
Featured
AZD-0156 is an orally bioavailable ataxia telangiectasia mutated (ATM) kinase inhibitor, with potential chemo-/radio-sensitizing and antineoplastic activities. |
1821428-35-6 |
DC20002 |
AZD-0284
Featured
AZD0284 is an inverse agonist of the nuclear receptor RORγ. In development for the treatment of plaque psoriasis vulgaris and respiratory tract disorders. |
2101291-07-8 |
DC11481 |
AZD-0364
Featured
AZD-0364 is a potent and selective ERK2 inhibitor extracted from patent WO2017080979A1, compound example 18, has an IC50 of 0.6 nM. |
2097416-76-5 |
DC20718 |
AZD-0837
AZD-0837 is a novel oral anticoagulant that after bioconversion to its active form is a potent and reversible thrombin inhibitor, has been investigated in phase II studies for prevention of stroke and systemic embolic events in patients with atrial fibril |
433937-93-0 |
DC10534 |
AZD0865(Linaprazan)
Featured
AZD0865 is a potent agent that inhibits gastric H(+),K(+)-ATPase activity and acid formation in vitro, with a fast onset of effect. |
248919-64-4 |
DC5054 |
AZD1080
Featured
AZD1080 is a selective, orally active, brain permeable GSK3 inhibitor, inhibits human GSK3α and GSK3β with Ki of 6.9 nM and 31 nM, respectively, shows >14-fold selectivity against CDK2, CDK5, CDK1 and Erk2. |
612487-72-6 |
DC23670 |
AZD-1092
AZD-1092 (GKA-80) is a potent Glucokinase (GK) activator with EC50 of 30 nM. |
871656-65-4 |
DC7060 |
AZD1152
Featured
AZD1152 (barasertib), pro-drug of barasertib-hQPA, is a selective Aurora B kinase inhibitor, AZD1152 inhibited the proliferation various types of human leukemia cells with an IC50 ranging from 3 nM to 40 nM. |
722543-31-9 |
DC5012 |
AZD-1208
Featured
AZD1208 is orally available, small molecule inhibitor of PIM kinases with potential antineoplastic activity. |
1204144-28-4 |
DC9731 |
AZD1283
Featured
AZD1283 is a potent antagonist of the P2Y12 receptor with EC50 of 3.0 ug/kg/min, TI >10; with binding IC50 of 11 nM. |
919351-41-0 |
DC20719 |
AZD-1305
AZD-1305 is a novel antiarrhythmic agent that predominantly blocks the rapid component of IKr, the L-type calcium current, and the inward sodium current in mammalian cells and ventricular cardiomyocytes. |
872045-91-5 |
DC20162 |
AZD1390
Featured
AZD1390 is a first-in-class orally available and CNS penetrant ATM inhibitor with an IC50 of 0.78 nM in cells and >10,000-fold selectivity over closely related members of the PIKK family of enzymes and excellent selectivity across a broad panel of kinases |
2089288-03-7 |
DC5032 |
AZD1480
Featured
AZD1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. Phase 1/2. |
935666-88-9 |
DC7572 |
AZD1981
Featured
AZD1981 is a potent, selective CRTh2 (DP2) receptor antagonist with IC50 of 4 nM, showing >1000-fold selectivity over more than 340 other enzymes and receptors, including DP1 |
802904-66-1 |
DC7073 |
AZD2014
AZD2014 is a novel mTOR inhibitor with IC50 of 2.8 nM; highly selective against multiple PI3K isoforms (α/β/γ/δ). |
1009298-59-2 |
DC10724 |
AZD2098
Featured
AZD2098 is a potent CC-chemokine receptor 4 (CCR4) inhibitor, used for asthma research. |
566203-88-1 |
DC1037 |
AZD2461
Featured
AZD2461 is a novel PARP inhibitor with potential to bypass Pgp-mediated resistance to Olaparib. |
1174043-16-3 |
DC7748 |
AZD-26(AKT-IN-1)
Featured
AZD-26 is an inhibitor of AKT. AZD-26 inhibits the phosphorylation of Thr308 on AKT in BT474 cells with an IC50 of 422 nM. |
1357158-81-6 |
DC11847 |
AZD2716
AZD2716(AZD-2716) is a novel potent, selective, orally bioavailable sPLA2 inhibitor with excellent plasma sPLA2 inhibition (IC50=0.1 nM). |
1845753-81-2 |
DC6302 |
AZD2858
Featured
AZD2858 is a selective GSK-3 inhibitor with an IC50 of 68 nM, activating Wnt signaling, increases bone mass in rats. |
486424-20-8 |
DC20050 |
AZD2906
AZD2906 is a selective glucocorticoid receptor (GR) agonist, with IC50s of 2.2, 0.3, 41.6 and 7.5 nM at GR in human, rat PBMC and human, rat whole blood, respectively. AZD2906 increases micronucleated immature erythrocytes (MIE) in the bone marrow of rats |
1034148-15-6 |
DC7799 |
AZD2932
Featured
AZD-2932 is a high affinity inhibitor of VEFGR-2 and PDGFR. |
883986-34-3 |
DC20724 |
AZD-3161
AZD-3161 is a potent and selective sodium channel Nav1.7 blocker for treatment of nociceptive pain. . |
1369501-46-1 |
DC20129 |
AZD3229
Featured
AZD3229 is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors. |
2248003-60-1 |
DC12265 |
AZD3229 Tosylate
AZD3229 Tosylate is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors. |
2248003-71-4 |
DC9946 |
Lanabecestat(AZD3293,LY-3314814)
AZD3293 is a potent and selective orally active, brain-permeable BACE1 inhibitor,currently in development as a potential treatment for early Alzheimer’s disease. |
1383982-64-6 |
DC7074 |
AZD-3463
Featured
AZD-3463 is an ALK/IGF1R inhibitor which overcomes multiple mechanisms of acquired resistance to crizotinib. |
1356962-20-3 |
DC5013 |
AZD3514
AZD3514 is a potent and oral androgen receptor with Ki of 2.2 μM and has ability of reducing AR protein expression. |
1240299-33-5 |
DC8472 |
AZD-3759
Featured
AZD3759 is an orally available inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. |
1626387-80-1 |
DC8400 |
AZD3839
Featured
AZD3839 is a potent and selective BACE1 inhibitor with Ki of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1. |
1227163-84-9 |
DC9263 |
AZD-3965
Featured
AZD3965 is a selective inhibitor of monocarboxylate transporter 1 (MCT1) with a binding affinity of 1.6 nM, is 6 fold selective over MCT2 and does not inhibit MCT4 at 10 μM. |
1448671-31-5 |
DC8060 |
AZD-3988
AZD-3988 is a potent and selective diacylglycerol acyltransferase (DGAT-1) inhibitor (IC50 = 0.6 nM). |
892489-52-0 |
DC20725 |
AZD 4017
AZD4017 is a potent, selective, and orally bioavailable human 11β-HSD1 with IC50 of 7 nM, shows no significant activity against 11β-HSD1 and 17β-HSD1, 17β-HSD3 (IC50>30 uM). |
1024033-43-9 |
DC23282 |
AZD 4320
AZD4320 is a BH3 mimetic and dual Bcl-2/Bcl-XL inhibitor with IC50 of <1 nM. |
1357576-48-7 |
DC1075 |
AZD4547
Featured
AZD4547 is a novel selective FGFR inhibitor targeting FGFR1, FGFR2, and FGFR3 with IC50 of of 0.2 nM, 2.5 nM, and 1.8 nM, respectively. |
1035270-39-3 |
DC11295 |
AZD-4573
AZD4573 is a CDK9 inhibitor with an IC50 of <3 nM extracted from patent US 20160376287 A1, example 14. |
2057509-72-3 |
DC10739 |
AZD4635
Featured
AZD4635 is a novel adenosine 2A receptor (A2AR) inhibitor with a Ki of 1.7 nM. |
1321514-06-0 |
DC23436 |
AZD-4818
AZD-4818 is a highly potent, selective CCR1 antagonist with pIC50 of 8.6, inhibits chemotaxia of human monocytes to MIP-1α in a concentration-dependent manner. |
1003566-93-5 |
DC10773 |
AZD5069
Featured
AZD-5069 is a potent and selective CXCR2 antagonist with the potential to inhibit neutrophil migration into the airways in patients with COPD. |
878385-84-3 |
DC10288 |
AZD5153 6-Hydroxy-2-naphthoic acid
Featured
AZD5153 6-Hydroxy-2-naphthoic acid is the 6-Hydroxy-2-naphthoic acid of AZD5153. AZD5153 is a potent, selective, and orally available BET/BRD4 bromodomain inhibitor; disrupts BRD4 with an IC50 of 1.7 nM. |
1869912-40-2 |
DC10774 |
AZD5153
Featured
AZD5153 is a potent bivalent triazolopyridazine based Bromodomain and Extraterminal (BET) Inhibitor. |
1869912-39-9 |
DC20727 |
AZD-5248
AZD-5248 is a potent, selective, first generation, oral inhibitor of dipeptidyl peptidase 1 (DPP1).. |
1254318-44-9 |
DC7368 |
AZD5363
Featured
AZD5363, a novel pyrrolopyrimidine-derived compound, inhibits all AKT isoforms (IC50 <10 nM). |
1143532-39-1 |
DC7369 |
AZD5438
Featured
AZD5438 is a potent inhibitor of CDK1/2/9 with IC50 of 16 nM/6 nM/20 nM. It is less potent to CDK5/6. |
602306-29-6 |
DC20716 |
AZD5576
AZD5576(AZD 5576) is a potent, highly selective, and orally bioavailable inhibitor of CDK9 with IC50 of < 5 nM, decreases phosphorylation of Ser2-RNAPII in cells with an IC50 of 96 nM. |
|
DC8232 |
AZD5582
Featured
AZD5582 is a novel class of dimeric Smac mimetics as potent IAP antagonist; binds potently to the BIR3 domains of cIAP1, cIAP2, and XIAP (IC50 = 15, 21, and 15 nM, respectively). |
1258392-53-8 |
DC7075 |
AZD-5597
AZD-5597 is potent CDK inhibitor with in vitro anti-proliferative effects against a range of cancer cell lines. |
924641-59-8 |
DC22009 |
AZD5718
Featured
AZD5718 (AZD-5718, AZD 5718) is a novel potent 5-lipoxygenase activating protein (FLAP) inhibitor with binding IC50 of 6.3 nM; exhibits LTB4 inhibition in human whole blood assays with IC50 of 39 nM; reduce the production of pro-inflammatory and vasoactive leukotrienes both in vitro and in vivo. |
2041075-86-7 |
DC20728 |
AZD-5718
AZD-5718 is an orally available small molecule, 5-lipoxygenase activating protein (FLAP) inhibitor.. |
|
DC22007 |
AZD5904
AZD5904 (AZD-5904) is a potent, selective irreversible, orally bioavailable myeloperoxidase (MPO) inhibitor with IC50 of 140 nM, similar potency in mouse and rat. |
618913-30-7 |
DC12553 |
AZD6088
AZD6088 (AZD-6088) is a potent and selective, orally bioavailable partial agonist of the M1 muscarinic receptor, reduces heat hyperalgesia in SNL rats with an EC50 of 46.6 nM.. |
1131451-40-5 |
DC1069 |
AZD6244 (Selumetinib,ARRY-142886)
Featured
AZD6244 (Selumetinib, ARRY-142886) is highly potent to inhibit MEK1 with IC50 of 14 nM. |
606143-52-6 |
DC8004 |
AZD6482
Featured
AZD6482 is a PI3Kβ inhibitor with IC50 of 10 nM, 8-, 87- and 109-fold more selective to PI3Kβ than PI3Kδ, PI3Kα and PI3Kγ. |
1173900-33-8 |
DC8468 |
AZD-6738
Featured
AZD6738 is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM. Phase 1/2. |
1352226-88-0 |
DC20731 |
AZD-7325
Featured
AZD-7325 is a potent, α2/3 functionally selective, partial GABAA receptor modulator with pKi of 9.51. |
942437-37-8 |
DC12490 |
AZD7507
Featured
AZD7507 (AZD-7507) is a potent, selective, orally available CSF-1R (c-FMS) with IC50 of 32 nM. |
1041852-85-0 |
DC8837 |
AZD-7547
Featured
AZD7545 is a novel, selective small-molecule inhibitor of PDHK2 (PDH kinase2) with an IC50 of 36.8 nM and 6.4 nM for PDHK1 and PDHK2 respectively. |
252017-04-2 |
DC20714 |
AZD-7594
Featured
AZD-7594 (AZ-13189620) is a potent, nonsteroidal, selective glucocorticoid receptor modulator (SGRM) with binding IC50 of 0.9 nM, shows no affinity for AR, PR, MR and ERα/β. |
1196509-60-0 |
DC20242 |
AZD-7624
Featured
AZD-7624 a potent, selective, inhaled p38α MAPK inhibitor for the treatment of chronic obstructive pulmonary disease. |
1095004-78-6 |
DC20278 |
AZD-7648
Featured
AZD-7648 is a potent and selective DNA-PK inhibitor. Anti-tumour activity. |
2230820-11-6 |
DC7076 |
AZD-7762
Featured
AZD7762 is a potent and selective inhibitor of Chk1 with IC50 of 5 nM; equally potent against Chk2 and less potent against CAM, Yes, Fyn, Lyn, Hck and Lck. |
860352-01-8 |
DC11723 |
AZD-7986(Brensocatib)
Featured
AZD-7986(Brensocatib) is a highly potent, reversible, and selective DPP1 inhibitor with enzyme and cell pIC50 of 8.4. |
1802148-05-5 |
DC5084 |
AZD-8055
Featured
AZD-8055 is a potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM. |
1009298-09-2 |
DC20733 |
AZD-8165
AZD-8165 is a potent, selective and oral thrombin inhibitor for treatment of thrombosis.. |
1201686-72-7 |
DC8380 |
AZD8186
Featured
AZD8186 is an inhibitor of the beta isoform of phosphoinositide-3 kinase (PI3K), with potential antineoplastic activity. |
1627494-13-6 |
DC20734 |
AZD-8309
AZD-8309 (AZD8309) is a potent and orally bioavailable CXCR2 antagonist that has been proposed to regulate the transmigration of neutrophils. |
333742-48-6 |
DC20735 |
AZD 8329
AZD8329 is a potent, selective 11β-HSD1 inhibitor with IC50 of 9 nM, displays excellent selectivity versus relatedd 11β-HSD2, 17β-HSD1 and 17β-HSD3 (IC50>30 uM). |
1048668-70-7 |
DC7077 |
AZD8330(ARRY-424704; ARRY-704)
Featured
AZD8330(ARRY-424704; ARRY-704) is a novel, selective, non-ATP competitive MEK 1/2 inhibitor with IC50 of 7 nM. |
869357-68-6 |
DC23437 |
AZD-8529
Featured
AZD8529 is a novel potent, selective mGluR2 positive allosteric modulator with EC50 of 195 nM, does not produce any positive allosteric modulator responses for mGluR1 and 3-8 subtypes. |
1092453-15-0 |
DC23408 |
AZD-8529 mesylate
Featured
AZD8529 is a novel potent, selective mGluR2 positive allosteric modulator with EC50 of 195 nM, does not produce any positive allosteric modulator responses for mGluR1 and 3-8 subtypes. |
1314217-69-0 |
DC10202 |
AZD8797
Featured
AZD8797 is an allosteric non-competitive modulator of the human CX3CR1 receptor; antagonizes CX3CL1 with IC50 values of 6 and 300 nM in B-lymphocyte cell line and human whole blood, respectively. |
911715-90-7 |
DC9879 |
AZD8835
Featured
AZD8835 ia a novel mixed inhibitor of PI3Kα and PI3Kδ with IC50 of 6.2 nM and 5.7 nM, respectively, also with selectivity against PI3Kβ (IC50=431 nM) and PI3Kγ (IC50=90 nM). |
1620576-64-8 |
DC10425 |
AZD9056 hydrochloride
AZD9056 is a selective orally active inhibitor of P2X7 which plays a significant role in inflammation and pain-causing diseases. |
345303-91-5 |
DC7006 |
AZD-9291(Osimertinib)
Featured
AZD-9291 is a potent and selective mutated forms EGFR inhibitor(Exon 19 deletion EGFR IC50=12.92 nM, L858R/T790M EGFR IC50= 11.44 nM, wild type EGFR IC50= 493.8 nM). |
1421373-65-0 |
DC8462 |
AZD-9291 mesylate (Osimertinib,Mereletinib)
Featured
AZD-9291 is a potent and selective mutated forms EGFR inhibitor(Exon 19 deletion EGFR IC50=12.92 nM, L858R/T790M EGFR IC50= 11.44 nM, wild type EGFR IC50= 493.8 nM). |
1421373-66-1 |
DC10112 |
AZD9362
AZD-9362 is dual IGF-IR/InsR inhibitor. |
1905412-80-7 |
DC9268 |
AZD9496
Featured
AZD9496 is a potent and orally bioavailable selective estrogen receptor downregulator(Ki=0.7 nM) and antagonist. |
1639042-08-2 |
DC11541 |
AZD-9567
AZD-9567 (AZD9567) is a potent, selective, non-steroidal and orally available selective glucocorticoid receptor modulator (SGRM) for treatment of rheumatoid arthritis.. |
1893415-00-3 |
DC11542 |
AZD-9567 monohydrate
AZD-9567 (AZD9567) is a potent, selective, non-steroidal and orally available selective glucocorticoid receptor modulator (SGRM) for treatment of rheumatoid arthritis.. |
1893415-64-9 |
DC20737 |
AZD-9819
AZD-9819 is an inhibitor of human neutrophil elastase for potential treatment of chronic obstructive pulmonary disease.. |
956907-23-6 |
DC11032 |
AZD9977
Featured
AZD9977 is a first-in-class, potent, selective, mineralocorticoid receptor (MR) modulator with IC50 of 0.37. 0.08 and 0.08 uM for human, mouse and rat MR, respectively. |
1850385-64-6 |
DC10245 |
Azelaic acid
Azelaic acid is an organic compound produced by the ozonolysis of oleic acid and possesses antibacterial, keratolytic, comedolytic, and anti-oxidant activity. |
123-99-9 |
DC9130 |
Azelastine HCl
Azelastine HCl is a potent, second-generation, selective, histamine antagonist. |
79307-93-0 |
DC8338 |
Azeliragon(PF-04494700,TTP488)
Featured
Azeliragon is an oral, small-molecule inhibitor of RAGE. |
603148-36-3 |
DCAPI1590 |
Azelnidipine
Azelnidipine is an L-type calcium channel protein inhibitor |
123524-52-7 |
DC20156 |
Azetidine-2-carboxylic acid
Featured
Azetidine-2-carboxylic acid is a non proteinogenic amino acid homologue of proline. Found in common beets. Azetidine-2-carboxylic acid can be misincorporated into proteins in place of proline in many species, including humans. Toxic and teratogenic agent. |
36476-78-5 |
DC4210 |
Azilsartan kamedoxomil
Featured
Azilsartan medoxomil is an angiotensin II receptor antagonist indicated for the treatment of mild to moderate essential hypertension. |
863031-24-7 |
DCAPI1469 |
azilsartan
Featured
Azilsartan(TAK-536) is a specific and potent angiotensin II type 1 receptor antagonist with IC50 of 2.6 nM. |
147403-03-0 |
DC9596 |
Azimilide (Dihydrochloride)
Azimilide 2Hcl(NE-10064 2Hcl) is a class III antiarrhythmic compound, inhibits I(Ks) and I(Kr) in guinea-pig cardiac myocytes and I(Ks) (minK) channels expressed in Xenopus oocytes. |
149888-94-8 |
DCAPI1362 |
Azithromycin (Zithromax)
Azithromycin (Zithromax) |
83905-01-5 |
DC4141 |
Azocosterol 2HCL
Azocosterol is a potential avian reproductive inhibitor. |
1249-84-9 |
DCAPI1225 |
Azomycin (2-Nitroimidazole)
Azomycin (2-Nitroimidazole) |
527-73-1 |
DC9818 |
Azoramide
Featured
Azoramide is a small-molecule modulator of the unfolded protein response with antidiabetic activity. |
932986-18-0 |
DC10992 |
Azosemide
Azosemide (Azosemidum) is a potent Na-K-Cl Cotransporter NKCC1 with IC50 of 0.246 and 0.197 uM for hNKCC1A and NKCC1B, being about 4-times more potent than bumetanide. |
27589-33-9 |
DC12497 |
(Z)-Azoxystrobin
Featured
Azoxystrobin is a systemic, broad-spectrum fungicide belonging to the class of methoxyacrylates,which are derived from the naturally-occurring strobilurins. |
143130-94-3 |
DC22953 |
AZSMO-23
AZSMO-23 (AZSMO 23, AZSMO23) is a potent hERG potassium channel (Kv11.1) activator that activates WT hERG pre-pulse and tail current with EC50 of 28.6 and 11.2 μM respectively. |
496793-75-0 |
DCAPI1341 |
Aztreonam (Azactam, Cayston)
Aztreonam (Azactam, Cayston) |
78110-38-0 |
DC21570 |
Azvudine
Featured
Azvudine (RO 0622) is a potent HCV NS5B RNA polymerase inhibitor, inhibits HCV replication in the replicon system with IC50 of 24 nM; inhibits RNA synthesis by HCV polymerases from either HCV genotypes 1a and 1b or containing S96T or S282T point mutations (IC50=10-100 nM). |
1011529-10-4 |
DC23756 |
Aβ polymerization stimulator O4
Aβ polymerization stimulator O4 is an orcein-related small molecule can drive polymerization of amyloid-β (Aβ). |
71939-12-3 |
DC12114 |
B I09
B I09 is an IRE-1 RNase inhibitor, with an IC50 of 1230 nM. |
1607803-67-7 |
DC10026 |
B02
Featured
B02 is a cell-permeable pyridinylvinyl-quinazolinone compound that is shown to specifically inhibit human RAD51 (IC50 = 27.4 µM). |
1290541-46-6 |
DC22010 |
B591
B591 (B-591) is a potent, specific pan-PI3K inhibitor with IC50 of 1.3/0.36/1.1/1.58 uM for PI3Kα/β/γ/δ, respectively. |
1498412-41-1 |